Patents Examined by Dong Jiang
  • Anti-GD2 antibodies
    Patent number: 8507657
    Abstract: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: August 13, 2013
    Assignee: Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou
  • Antagonists of IL-17A, IL-17F, and IL-23P19
    Patent number: 8496936
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: July 30, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • DNA encoding antibody molecules having specificity for human IL-6
    Patent number: 8486662
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: July 16, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Richard Evan Gelinas, Mitra Choudhury Singhal, Yi Zhang, Andrew George Popplewell, Ralph Adams
  • Polynucleotides encoding antibodies that bind both IL-17A and IL-17F
    Patent number: 8481288
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: July 9, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • IL-21 variants
    Patent number: 8475784
    Abstract: IL-21 variants are provided wherein amino acids have been deleted in the region consisting of amino acid residues no. 65 to 98.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: July 2, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen
  • Methods for treating allergic airway inflammation, airway hypersensitivity, and eosinophilia
    Patent number: 8454955
    Abstract: The invention provides a method of screening a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, comprising using an IL-17RB positive NKT cell, as well as a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, containing a substance capable of inhibiting or eliminating the Th2 cell-like function of an IL-17RB positive NKT cell as an active ingredient.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: June 4, 2013
    Assignee: Riken
    Inventors: Hiroshi Watarai, Masaru Taniguchi
  • Nucleic acids encoding IL-17 homologous receptor-like polypeptides and therapeutic uses thereof
    Patent number: 8455217
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: June 4, 2013
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul Godowski, Christopher Grimaldi, Austin Gurney, William I. Wood
  • IL-21 derivatives and variants
    Patent number: 8450459
    Abstract: The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: May 28, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Bernd Peschke, Christine Bruun Schiødt, Helle Wöldike, Florencio Zaragoza Dörwald, Anne Worsaae
  • Antibodies against interleukin-18 binding protein, their preparation and use
    Patent number: 8436148
    Abstract: Interleukin-18 binding proteins which are capable of binding IL-18 and/or modulating and/or blocking IL-18 activity are provided. Methods for their isolation and recombinant production, DNAs encoding them, DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: May 7, 2013
    Inventors: Charles Dinarello, Menachem Rubinstein, Soo Hyun Kim, Daniela Novick
  • DNA encoding antibody molecules which bind human IL-17
    Patent number: 8435761
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods of producing the antibody molecules.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: May 7, 2013
    Assignee: UCB Pharma SA
    Inventors: Stephen Edward Rapecki, Andrew George Popplewell, Ralph Adams
  • Peptide antagonist of interleukin-15 activity
    Patent number: 8431524
    Abstract: The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor ? (TNF?) induction and the expression of IL-8 and IL-6 by the IL-15 receptor ? subunit (IL-15R?), all these effects mediated by the binding of the peptide to the IL-15R?. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15R? is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: April 30, 2013
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Alicia Santos Savio, Osvaldo Reyes Acosta, Haydee Geronimo Perez, Hilda Elisa Garay Perez, Yunier Rodriguez Alvarez, Gerardo Enríque Guillen Nieto
  • Antibody modulators of hepatocyte growth factor activator
    Patent number: 8399629
    Abstract: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: March 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Yan Wu
  • IL-21 variant nucleic acids
    Patent number: 8383367
    Abstract: IL-21 variants nucleic acid sequences are provided that encode a peptide having deletions and zero to ten conservative amino acid substitutions in the region of amino acid residues 65-96 of SEQ ID. NO:2.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: February 26, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Siv Annegrethe Hjorth, Kent Bodensgaard, Dennis Madsen
  • Methods of treatment using anti-human IL-21 monoclonal antibodies
    Patent number: 8361470
    Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, TH cells or TH17 cells.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: January 29, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
  • Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof
    Patent number: 8338132
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: December 25, 2012
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Audrey Goddard, Paul Godowski, J. Christopher Grimaldi, Austin Gurney, Hanzhong Li, Kenneth Hillan, Sarah G. Hymowitz, Daniel Tumas, Melissa A. Starovasnik, Menno VanLookeren, Richard Vandlen, Colin Watanabe, P. Mickey Williams, William I. Wood, Daniel Yansura
  • Methods of inhibiting inflammation with antagonists to IL-17A, IL-17F, and IL-23P19
    Patent number: 8333968
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: December 18, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
  • Nucleic acid molecules encoding neutralising antibodies having specificity for human IL-17
    Patent number: 8329431
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: December 11, 2012
    Assignee: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Engineered anti-IL-23R antibodies
    Patent number: 8309085
    Abstract: Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: November 13, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Leonard G. Presta
  • Antibody molecules which bind IL-17A and IL-17F
    Patent number: 8303953
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: November 6, 2012
    Assignee: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Use of interleukin 17E for the treatment of cancer
    Patent number: 8287851
    Abstract: The use of interleukin 17E to inhibit tumor growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumor growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.
    Type: Grant
    Filed: March 8, 2006
    Date of Patent: October 16, 2012
    Assignee: Lorus Therapeutics Inc.
    Inventors: Jim A. Wright, Aiping H. Young, Yoon Lee, Ming Yu Cao